Alm. Brand A-S Un Aktie

3,55USD
±0,00USD
±0,00%
26.11.2021

ISIN: US02008B1035 / Symbol: ABDBY

  Kaufen  
Verkaufen
oder
Werbung

Times and Sales (XETRA)

ZeitKursUmsatz
Zur Zeit stehen keine Daten zur Verfügung
weiter
Werbung

Aktuelle News zu

23:10 UhrProtagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022
23:10 UhrFür Tesla: Musk sucht auf Twitter nach neuer Rechtsabteilung - und erntet Kritik
23:08 UhrKaryopharm to Present New Selinexor Data at the 2022 American Society of Clinical Oncology Annual Meeting
23:07 UhrNASA Supports Small Business Research to Power Future Exploration
23:05 UhrSILVERCORP REPORTS ADJUSTED EARNINGS OF $52.4 MILLION, $0.30 PER SHARE, AND CASH FLOW FROM OPERATIONS OF $107.4 MILLION FOR FISCAL 2022
23:05 UhrNew Research Demonstrates Genetic Information Can Transform Cancer Care, Guidelines Remain a Barrier to Patient Access
23:05 UhrElevation Oncology to Present Initial Seribantumab Proof-of-Concept Data from Phase 2 CRESTONE Study in Patients with Tumors Harboring NRG1 Fusions at ASCO 2022
23:05 UhrSILVERCORP REPORTS ADJUSTED EARNINGS OF $52.4 MILLION, $0.30 PER SHARE, AND CASH FLOW FROM OPERATIONS OF $107.4 MILLION FOR FISCAL 2022
23:05 UhrPuma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting
23:01 UhrElectra Makes Steady Progress in Q1 2022 Towards Commissioning its Cobalt Refinery
23:01 UhrFDA Flexibilities, Collaboration to Yield Millions of Bottles of Specialized Medical Infant Formula in Coming Months to Increase U.S. Supply
23:01 UhrMILE MARKER INDUSTRIES ANNOUNCES MANAGEMENT CHANGES
23:01 UhrI-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab
23:01 UhrGracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting CAR-T GC012F for Relapsed/Refractory Multiple Myeloma at 2022 ASCO Annual Meeting
23:01 UhrElectra Makes Steady Progress in Q1 2022 Towards Commissioning its Cobalt Refinery
23:01 UhrXencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors
23:01 UhrSpectrum Pharmaceuticals to Present Data at 2022 ASCO Highlighting the Potential Predictive Capabilities of ctDNA as a Biomarker for Poziotinib Treatment Response
23:00 UhrSQI Diagnostics Reports Second Quarter 2022 Results
23:00 UhrTriNet to Participate at the Stifel 2022 Cross Sector Insight Conference
23:00 UhrCTI BioPharma Presents Pivotal Data from Pacritinib Program at the 2022 American Society of Clinical Oncology Annual Meeting
23:00 UhrNext-Generation Immunotherapy Drug Shows Continued Promise in Several Advanced-Stage Cancers
23:00 UhrMARTIN UNIVERSITY ANNOUNCES DATA SECURITY INCIDENT
23:00 UhrLeap Therapeutics to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting
23:00 UhrBelong.Life Real-World Patient Research Analyzes the Impact of COVID-19 on Cancer Diagnosis in ASCO 2022 Abstract
23:00 UhrZovio Advances Turnaround Plan and Strengthens Financial Position
23:00 UhrNEW DATA SHOWCASES HOW AMGEN IS ADVANCING ALL ANGLES OF CANCER CARE THROUGH INNOVATIVE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2022
23:00 UhrInvestigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer
23:00 UhrLilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
23:00 UhrSQI Diagnostics Reports Second Quarter 2022 Results
23:00 UhrLANESBOROUGH REIT REPORTS 2022 FIRST QUARTER RESULTS
23:00 UhrForan Announces Voting Results from 2022 AGSM
23:00 UhrMinto Apartment REIT Reports Voting Results from Annual General Meeting of Unitholders
23:00 UhrLinamar Corporation Announces Voting Results from Annual General Meeting
23:00 UhrIpsen: ASCO 2022: New Cabometyx® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer
23:00 UhrMerus Announces Publication of Abstract of Zenocutuzumab in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
22:57 UhrDenali Capital Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing May 31, 2022.
22:54 UhrThe Doctors Company Names Megan Mahoney, MD, MBA, to Board of Governors
22:51 UhrQUESTEX ANNOUNCES SECURITYHOLDER APPROVAL OF PLAN OF ARRANGEMENT
22:48 UhrFCP MAKES FIRST MULTIFAMILY INVESTMENT IN COLORADO WITH RECAP OF IVY CROSSING APARTMENTS IN DENVER
22:47 UhrTerranea Resort Invites Guests To Celebrate World Oceans Day
22:44 UhrLowe's Guardian Angel: A Place for Caregiver Career Advancement
22:42 UhrPort of Montreal welcomes several new vessels including CMA CGM MONTREAL
22:40 UhrCengage Group Announces Preliminary 2022 Fiscal Fourth Quarter and Year-End Results; Expects to Meet Financial Outlook Driven by Strength of Portfolio of Businesses that Empower Student Choice
22:37 UhrLENNAR LAUNCHES NEW INLAND NORTHWEST MARKET
22:35 UhrKAR Auction Services, Inc. to Host Investor Update Call
22:33 UhrDogness Reports Fiscal Six Months 2022 Financial Results
22:30 UhrStockfish to Represent Weyerhaeuser at Nareit REITweek: 2022 Investor Conference
22:30 UhrCASI PHARMACEUTICALS ANNOUNCES REVERSE STOCK SPLIT
22:30 UhrProtalix BioTherapeutics Announces Poster Presentations at the 2022 Program: 7th Update on Fabry Disease
22:30 UhrGates Industrial to Participate in the 2022 KeyBanc Industrials & Basic Materials Conference
finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln